Lily Allen is opening up about why she's so candid about motherhood with her two kids. The singer spoke with British Vogue in a new interview and discussed why she finds it important to be candid with ...

If you play pickleball in Miami, chances are you owe a debt of gratitude to Lily Azel … even if you may not know her name. After all, Azel is not a pro player. She’s not a coach. And she’s not an ...

Lily-Rose Depp looked effortlessly chic as she joined her mum Vanessa Paradis at the Chanel Paris catwalk show. The French-American actress, 26, was among the stars who arrived for the Chanel ...

Investing.com - Citizens has reiterated its Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ:LRMR), following a call with the CEO of the Friedreich’s Ataxia Research ...

The Spider Lily General is a Tokachi Range Myth in Ghost of Yotei. This Myth tells the tale of a famed general who settled down and raised a daughter, only for tragedy to strike once he began to train ...

Larimar Therapeutics recently announced positive results from its long-term open label study of nomlabofusp in participants with Friedreich's Ataxia, showing benefits at both 25 mg and 50 mg doses ...

Lily King’s new novel, “Heart the Lover,” is a profoundly affecting story of romantic entanglement by a master of the genre. By Lauren Christensen Lauren Christensen is an editor at the Book Review ...

In other recent news, Larimar Therapeutics has reported notable developments concerning its ongoing study of nomlabofusp for Friedreich’s ataxia. The company announced positive data, highlighting that ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Larimar Therapeutics ( (LRMR)) has issued ...

In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year ...

BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...